Advertisement
BDX vs TMO
Which Stock Would AI Choose? Becton Dickinson (BDX) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BDX (Becton, Dickinson and Company) has shifted to a focused, pure-play medical technology (MedTech) business following its life sciences separation, while TMO (Thermo Fisher Scientific) remains a diversified life sciences tools and services leader.
- TMO is trading near its 52-week high on accelerating organic growth and raised guidance, whereas BDX shows strong short-term momentum but a negative year-to-date return amid restructuring and targeted headwinds.
- Relative performance has favored TMO, which has posted broader-based revenue growth and more consistent analyst upgrades than BDX.
- Tickeron AI Verdict: The AI would currently favor TMO for its more consistent uptrend, stronger earnings momentum, and clearer near-term catalysts relative to BDX.
- For more context, explore BDX Major News and BDX Today's Price Move, as well as TMO Major News and TMO Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors comparing large-cap healthcare names often weigh a diversified life sciences giant against a focused medical technology leader. That is exactly the contrast between TMO and BDX. Thermo Fisher Scientific serves pharmaceutical, biotech, academic, and diagnostic customers across a broad portfolio, while Becton Dickinson has narrowed its focus to medical devices and consumables following a major business separation. Both are blue-chip healthcare franchises, yet their recent market positioning has diverged. This stock comparison is most relevant for long-term investors and active traders seeking to understand how business model, growth drivers, and momentum differ between two sector leaders operating in distinct parts of the healthcare value chain.
BDX Overview and Recent Performance
BDX, Becton, Dickinson and Company (commonly known as BD), is a medical technology company that manufactures and sells medical supplies, devices, and diagnostic products. In recent months, BD completed the separation of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation, transforming the company into a more focused "New BD" organized around segments such as Medical Essentials, Connected Care, BioPharma Systems, and Interventional.
Recent market activity has been mixed for BDX. The stock has rallied meaningfully over the trailing three to six months, supported by a landmark partnership with the U.S. government that outlines roughly $19 billion in planned domestic manufacturing investments and by positive clinical data, including nine-month results from the AGILITY trial for its Revello vascular covered stent. However, shares remain lower on a year-to-date basis, reflecting investor caution around several defined pressures: the Alaris infusion pump remediation, persistent weakness in China, declining vaccine demand, and tariff-related cost headwinds. Management has nonetheless raised full-year adjusted earnings guidance, signaling confidence in underlying execution.
TMO Overview and Recent Performance
TMO, Thermo Fisher Scientific, is a global leader in life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract research organization (CRO) offerings. Its customers span pharmaceutical and biotechnology firms, hospitals, universities, and government institutions, giving the company broad exposure across the healthcare and research landscape.
Recent market activity has favored TMO, with shares trading near their 52-week high and posting a solid year-to-date gain. In its most recent quarter, the company reported revenue growth of roughly 9% year over year, with organic growth around 6% and adjusted earnings per share up about 15%, exceeding expectations. Management raised full-year revenue and earnings guidance, citing strength in pharma and biotech demand and improving momentum in China. The company also completed the divestiture of its microbiology business and advanced strategic acquisitions, including Clario, while many sell-side analysts raised price targets. These developments have reinforced a constructive, broad-based sentiment shift toward the stock.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, statistics, and set of covered securities. Because market conditions change constantly, only a subset of these bots is well suited to the current environment at any given time. Tickeron curates that subset in its Trending AI Robots section, where traders can review the strategies and track records of the bots currently generating the strongest signals. The page highlights bots across a range of styles, from short-term swing trading to longer-horizon trend following, so users can compare performance metrics and find approaches that align with their own objectives. Explore Trending AI Robots to see which automated strategies are gaining traction now.
Head-to-Head Comparison
The two companies operate in related but distinct parts of healthcare. TMO is a diversified life sciences and diagnostics franchise whose growth is tied to biopharma research and development (R&D) spending, clinical trial activity, and laboratory demand. BDX, by contrast, is now a more concentrated MedTech business driven by medical consumables, drug delivery, patient monitoring, and interventional products. This difference creates distinct risk profiles: TMO is more exposed to cyclical research funding and biopharma budgets, while BDX is more exposed to procedure volumes, hospital purchasing, and regulatory or product-quality issues.
On recent momentum, the contrast is clear. TMO is benefiting from a broad-based demand recovery, raised guidance, and a steady stream of analyst target increases, positioning it near multi-year highs. BDX has strong short-term upside but faces more concentrated headwinds, including the Alaris remediation, China softness, and tariff costs, which have kept year-to-date performance negative. In terms of valuation and market positioning, TMO commands a premium multiple consistent with its scale and growth consistency, while BDX trades at a lower multiple that reflects its ongoing portfolio reset and execution uncertainties.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, guidance trends, and relative positioning, Tickeron's AI would currently favor TMO over BDX. Thermo Fisher exhibits a more consistent uptrend, accelerating organic growth, and a clearer path of positive catalysts, including a recovering biopharma channel and constructive analyst revisions. Becton Dickinson's recent rally is notable, but its momentum has been more volatile and complicated by restructuring and targeted headwinds. The AI assessment is probabilistic rather than definitive, reflecting the balance of current data rather than a guarantee of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Buy and TMO is a StrongBuy.
BDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BDX turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 54 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 134 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 114 of 218 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.364) is normal, around the industry mean (4.964). P/E Ratio (63.819) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.143). BDX has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.005). P/S Ratio (2.290) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 56 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMO just turned positive on November 09, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 147 of 248 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (67.298). P/E Ratio (37.333) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
BDX | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 59 | 63 | |
SMR RATING 1..100 | 85 | 60 | |
PRICE GROWTH RATING 1..100 | 3 | 15 | |
P/E GROWTH RATING 1..100 | 5 | 28 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is in the same range as BDX (75). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Profit vs Risk Rating (59) in the Medical Specialties industry is in the same range as TMO (63). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BDX (85). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (3) in the Medical Specialties industry is in the same range as TMO (15). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
BDX's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as TMO (28). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
| BDX | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | N/A |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 50% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 52% | 1 day ago 63% |
| Advances ODDS (%) | 6 days ago 46% | 1 day ago 63% |
| Declines ODDS (%) | 15 days ago 42% | 9 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 51% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 52% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- TMO’s TA Score: 4 bullish, 3 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +8.38% price change this week, while TMO (@Medical Specialties) price change was +5.71% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.11%. For the same industry, the average monthly price growth was -5.15%, and the average quarterly price growth was +40.44%.
Reported Earning Dates
BDX is expected to report earnings on Feb 04, 2027.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.11% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +3.87% | ||
| A - TMO | 74% Closely correlated | +3.10% | ||
| DHR - TMO | 73% Closely correlated | +2.12% | ||
| RVTY - TMO | 70% Closely correlated | +3.62% | ||
| BRKR - TMO | 67% Closely correlated | +8.53% | ||
| IQV - TMO | 67% Closely correlated | +2.58% | ||
More | ||||